Pancreatic remnant fate by Hać, S. et al.
Folia Morphol. 
 Vol. 74, No. 1, pp. 56–60
DOI: 10.5603/FM.2015.0009 
Copyright © 2015 Via Medica
ISSN 0015–5659 
www.fm.viamedica.pl
O R I G I N A L   A R T I C L E
56
Address for correspondence: S. Hać, MD, PhD, Department of General Endocrine and Transplant Surgery, Medical University of Gdansk,  
ul. Dębinki 7, 80–952 Gdańsk, Poland, tel: +48 58 349 3029, e-mail: sthac@gumed.edu.pl
Pancreatic remnant fate
S. Hać1, J. Pieńkowska2, I. Madejewska1, D. Łaski1, J. Kostro1, P. Mroczkowski3,  
M. Studniarek2, Z. Śledziński1
1Department of General Endocrine and Transplant Surgery, Medical University of Gdansk, Poland 
2Department of Radiology Medical University of Gdansk, Poland 
3Department of Visceral and Vascular Surgery, University of Magdeburg, Germany
Received 1 July 2014; Accepted 13 July 2014]
There is eternal discussion on the best surgical method of pancreatoduodenectomy 
and reconstruction method. Several different methods of pancreatic stump ana-
stomosis exist. The most popular argument taken into account in the discussion is 
the frequency of early postoperative complications. Relatively fewer papers analyse 
the late functional outcome of pancreatic surgery and the method of anastomosis 
employed. Authors presented short series of 12 patients after pancreatic surgery 
with analysis of pancreatic remnant morphology and function. Pancreatic remnant 
volume, pancreatic duct distension and stool elastase-1 test were analysed. There 
was no correlation of pancreatic exo- or endocrine insufficiency with the volume 
of pancreatic remnant or the kind of surgery or anastomosis performed. (Folia 
Morphol 2015; 74, 1: 56–60)
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INTRODUCTION
Pancreatoduodenectomy (PD) is the procedure with 
100 years history and is accepted as treatment of 
choice in pancreato-biliary area malignancies [12]. The 
pancreas is composed of two embryo buds resulting 
in complicated configurational anatomy of pancreatic 
duct [8]. Many investigations are carried out analysing 
anatomical, technical, physical and histological factors 
related to complications of pancreatic anastomosis. 
Simultaneously discussion of superiority of technical 
variants of operation is ongoing. A large effort is made 
to find the best management. Short time efficacy of 
surgery is measured usually by means of complications 
and mortality rate after PD [18, 19, 28]. The large 
series indicate the influence of parenchyma texture, 
pancreatic duct size, intraoperative blood loss and 
patient comorbidity [1, 7, 11, 22, 24]. The late outcome 
of PD is monitored by oncological results and quality 
of life. The objective of pancreatic remnant condition 
is established on the basis of pancreatic function pre-
servation and imaging criteria [16, 24, 27]. Several 
investigators supposed to find the correlation between 
the technique of pancreatic remnant anastomosis and 
its function [9, 16, 27]. The reduction of glandular 
tissue, pancreatic remnant duct patency, deficiency of 
duodenal stimulation to pancreas and inactivation of 
pancreatic enzymes are considered important factors 
of maldigestion related to pancreatic function [24]. The 
pancreatic remnant duct dilatation in postoperative 
course is thought to be the symptom of progressive 
remnant damage or outflow obstruction related to 
anastomosis method or technique [27].
MaTeRIals aND MeThODs
The study protocol was approved by Local Ethic 
Committee of Medical University of Gdansk, Poland 
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(No NKEBN/485-236/2009). Twelve  patients after PD 
were identified in outpatient clinic. All participants 
signed informed consent to participate in the study 
according to the protocol. The mean patients’ age 
was 66.3 (from 43 to 77) years, the male-female ratio 
was 8:4. Patients underwent PD from 3 to 86 (mean 
36.6) months prior to the enrolment. The primary 
diagnosis, treatment administrated, weight main-
tenance, body mass index (BMI) are summarised in 
Table 1. Eight patients underwent standard Whipple 
resection with pancreatogastrostomy (PG), 4 unde-
rwent pylorus preserving pancreatic head resection 
with side-to-side pancreatojejunostomy (PP-PJ).  
Pancreatic malfunction history and stool elasta-
se-1 test concentration based on ELISA method (Cat. 
No: 07, ScheBo Stool Test, Giessen, Germany) was 
performed. Stool samples were obtained during nor-
mal feeding period using E1-Quick-Prep tube (Cat. 
No: 07-Quick, ScheBo Stool Test, Giessen, Germany). 
Patients did not receive proton pump inhibitors and 
did not discontinue enzyme supplements, according 
to manufacturer information.
Three-phase (arterial, pancreatic, and portal 
venous phases) contrast-enhanced multi detector 
computed tomography (MDCT) was performed with 
a 64-slice MDCT scanner (LightSpeed VCT; GE He-
althcare) for 6 patients. A dose of 1.0 mL/kg body 
weight of the 300 mgI/mL nonionic contrast material 
Iohexol (Omnipaque, GE HEALTHCARE AS, Norway) 
was administered intravenously at a rate of 3 mL/s 
by means of a power injector (Auto Enhance A-50; 
Nemoto Kyorindo, Tokyo, Japan). The scanning delay 
was individually determined with a test bolus injection 
technique. Pancreatic phase images were obtained 
after scanning of the arterial phase imaging during 
a single breath hold with an interscan delay 10 s. 
The mean injection to scan delay for arterial phase 
imaging was 21.7 s and that for pancreatic phase 
imaging was 33.7 s. The example of image is shown 
on Figure 1. 
For the subsequent imaging analysis, the pancrea-
tic phase images of 2.5-mm collimation obtained with 
64-slice MDCT. From these axial images of 0.625-mm 
to 2.5-mm slice thickness, oblique-coronal multipla-
nar reconstruction (MPR) images of 0.7-mm slice 
thickness were generated at 0.7-mm intervals on 
a computer workstation (Advantage Workstation 4.4; 
GE Healthcare) by broad-certified radiologist who was 
the study coordinator. All data were compared to the 
situation prior to the surgery is available. Pancreatic 
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remnant was digitally measured, pancreatic volume-
try (Fig. 2) as well as pancreatic duct diameter at the 
anastomosis and proximal to it.
ResUlTs
Nine of twelve patients underwent MDCT without 
intolerance and all scans quality was suitable for ana-
lysis. Nine patients decline contrast enhanced CT and 
accept only standard examination. From this reason 
only limited morphological data are available in that 
group. Pancreatic duct mean diameter before surgery 
was 1.93 mm (1–10 mm). On follow up the mean size 
of pancreatic remnant duct diameter was 3.14 mm. 
Three patients with distended pre operatively 
pancreatic duct presented marked diameter reduction 
(patient no. 1, 2 and 10). Seven patients has incre-
ased pancreatic remnant duct diameter, the other 
3 did not presented diameter enlargement. Three of 
four patients after PJ did not presented pancreatic 
remnant duct distension. The pancreatic parenchyma 
and duct contain calcifications only in patient no. 
15. There was no chronic opioids consumption in 
analysed group. Patient does not present history of 
pancreatic exocrine and endocrine malfunction. Three 
patients have gain weight postoperatively, other 
9 have weight loss from 2.8 to 20.9 kg. Patients BMI 
post operatively vary from 18.6 to 27.8 kg/m2 and 
was qualified as well-nourished or obese (3 patients 
had BMI more than 25 kg/m2). Detailed dietary in-
formation did not revealed symptoms of pancreatic 
exocrine malfunction. Elastase-1 stool concentration 
and morphologic data are summarised in Table 1. 
There was no correlation between elastase-1 stool 
concentration and pancreatic remnant volume or 
pancreatic remnant duct diameter.
DIsCUssION
The biology of pancreato-biliary malignancy resul-
ted in limited number of patients suitable for long 
term follow-up.
Early outcome after PD is monitored with pancrea-
tic fistula rate, morbidity and postoperative mortality. 
During last two decades considerable progress was 
achieved in pancreatic surgery and complication rate 
significant reduction. No randomised controled trial 
Figure 1. Pancreatic remnant duct identification and measurement on computed tomography scan (pancreatic duct is indicated between arrows).
Figure 2. Pancreatic remnant volumetry as the result of computed 
tomography digital processing.
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is available on the superiority of PG or PJ concerning 
early postoperative outcome and complications rate 
[2, 3, 5, 6]. Some studies documented fewer posto-
perative pancreatic fistula rates after PG [16, 21]. 
Uncomplicated PD resulted in several inconvenien-
ce for the patient after recovery. Some of them are the 
results of new configuration of digestive tract, food 
intake limitation, dietary restriction, intolerance and 
malabsorption. The other relatively late problem after 
PD is pancreatic exo- and endocrine malfunction. The 
reason of pancreatic exocrine insufficiency is thought 
to be the pancreatic glandular tissue deficit, remnant 
duct occlusion or permanent pancreatic enzyme ina-
ctivation in the stomach acid environment [17]. There 
are data confirming the time dependent pancreatic 
duct dilatation within few months after PD [24, 27]. 
The pylorus preserving PD is thought to be beneficial 
concerning lower risk of postoperative dumping syn-
drome and stomal ulceration [23]. Some experimental 
data confirm the difference in the pancreatic rem-
nant changes after different anastomosis technique 
applied [4]. The most data support the beneficial use 
of duct-to-mucosa PJ [4, 27]. This technique gives the 
best opportunity to control the patency of pancreatic 
duct during surgery and gives perfect adaptation of 
mucosa-to-mucosa resulting in the lowest risk of late 
scar stricture [10, 28].
Our series revealed, similarly to some other 
authors, more frequent increase of pancreatic rem-
nant duct diameter after PG comparing with PJ. This 
observation did not correspond to clinical manifesta-
tion of pancreatic exocrine insufficiency.
Some authors document no significant differen-
ces of pancreatic exocrine insufficiency, nutritional 
status, gastric emptying and pancreatic duct dia-
meter [9]. However the diameter of pancreatic duct 
before the operation and on follow-up increased 
in both PJ and PG group in some series. Jang et al. 
[16] evaluated pancreatic exocrine function after 
PJ vs. PG and noticed severe exocrine insufficiency 
after later operation with marked pancreatic duct 
dilatation. However authors use only history and 
clinical presentation to establish exocrine pancreatic 
insufficiency. Passaux et al. [24] reported high rate 
of pancreatic exocrine insufficiency (95%) after PD 
and pancreatico-gastro anastomosis on small co-
hort of patients. Authors use stool elastase-1 test. 
In that series the magnetic resonance cholangio 
pancreatography of pancreatic remnant duct perme-
ability was analysed and all patients presented duct 
dilatation. The results of pancreatic function tests 
were in accordance to observed duct patency. Surpri-
singly, pancreatic remnant duct diameter observed 
in “patent” group was larger than in “obstructed” 
one [24].
Similarly, in our series marked elastase-1 stool 
concentration decrease regardless of pancreatic ana-
stomosis performed. Surprisingly, patients with low 
elastase-1 level without enzyme supplement therapy 
did not presented typical symptoms of pancreatic 
exocrine insufficiency or malnutrition.
Many cohorts are based on limited number of 
patients ranging from 19 to 73 [9, 13, 16, 20, 24–27]. 
Surprisingly, the largest series from Hyodo et al. [13] 
documented negligible pancreatic duct dilatation 
after PG and no symptoms of exo- and endocrine in-
sufficiency. However, Japan group use clinical criteria 
of pancreatic exocrine function. Authors described 
in details PG modification with pancreatic stump 
invagination and gastric mucosa approximation [13]. 
This observation on the largest available group might 
guide the discussion back to technical details and 
material used to manage pancreato-enteral anasto-
mosis as the detrimental factor of late operatively 
outcome. The biology of the primary reason for PD 
resulted in small group of follow-up series. On the 
other hand, chronic pancreatitis patients after PD are 
not candidates to be compared because of ongoing 
inflammatory process of pancreatic remnant and 
progressive damage resulting in pancreatic function 
loss. Ishii et al. [14] analysed postoperative pancre-
atic juice output and exocrine function based on 
13C-dipeptide-(Bz-Tyr-Ala) breath test after PD. Small 
group operated with Roux-en-Y reconstruction pre-
sented marked difference in pancreatic juice volume 
and amylase concentration. All patients with primary 
diagnosis of chronic pancreatitis (CP) and pancreatic 
cancer (PC) presented significantly lower values than 
duodenal papillary carcinoma one [14]. All patients 
with primary PC met also microscopic criteria of CP 
in the remnant on transection site. The proportion of 
fibrosis to glandular tissue at pancreatic transaction 
site of PD performed because of PC ranges from 47% 
to 55% in different series [15, 27]. Similar result is 
observer in presented series.
Comparing several data concerning pancreatic 
remnant function there is no uniform methodology 
used for exocrine function evaluation thus data seems 
to be relatively difficult for comparison and inter-
pretation.
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CONClUsIONs
Our short series revealed no clinical difference 
between PG and PJ in follow up.
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